Search

Your search keyword '"Maqhuzu, Phillen"' showing total 18 results
Start Over Author "Maqhuzu, Phillen" Publication Year Range Last 50 years
18 results on '"Maqhuzu, Phillen"'

1. Disease trajectories in interstitial lung diseases – data from the EXCITING-ILD registry

Author

Buschulte, Katharina, primary, Kabitz, Hans-Joachim, additional, Hagmeyer, Lars, additional, Hammerl, Peter, additional, Esselmann, Albert, additional, Wiederhold, Conrad, additional, Skowasch, Dirk, additional, Stolpe, Christoph, additional, Joest, Marcus, additional, Veitshans, Stefan, additional, Höffgen, Marc, additional, Maqhuzu, Phillen, additional, Schwarzkopf, Larissa, additional, Hellmann, Andreas, additional, Pfeifer, Michael, additional, Behr, Jürgen, additional, Karpavicius, Rainer, additional, Günther, Andreas, additional, Polke, Markus, additional, Höger, Philipp, additional, Somogyi, Vivien, additional, Lederer, Christoph, additional, Markart, Philipp, additional, and Kreuter, Michael, additional

Published
2024
Full Text
View/download PDF

2. Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry

Author

Buschulte, Katharina, primary, Kabitz, Hans-Joachim, additional, Hagmeyer, Lars, additional, Hammerl, Peter, additional, Esselmann, Albert, additional, Wiederhold, Conrad, additional, Skowasch, Dirk, additional, Stolpe, Christoph, additional, Joest, Marcus, additional, Veitshans, Stefan, additional, Höffgen, Marc, additional, Maqhuzu, Phillen, additional, Schwarzkopf, Larissa, additional, Hellmann, Andreas, additional, Pfeifer, Michael, additional, Behr, Jürgen, additional, Karpavicius, Rainer, additional, Günther, Andreas, additional, Polke, Markus, additional, Höger, Philipp, additional, Somogyi, Vivien, additional, Lederer, Christoph, additional, Markart, Philipp, additional, and Kreuter, Michael, additional

Published
2024
Full Text
View/download PDF

5. Healthcare resource utilisation and medical costs for children with interstitial lung diseases (chILD) in Europe

Author

Seidi, Elias, Schwerk, Nicolaus, Carlens, Julia, Wetzke, Martin, Cunningham, Steve, Emiralioğlu, Nagehan, Kiper, Nural, Lange, Joanna, Krenke, Katarzyna, Ullmann, Nicola, Krikovszky, Dora, Maqhuzu, Phillen, Griese, Charlotte A, Schwarzkopt, Larissa, and Griese, Matthias

Subjects
Europe, Pulmonary and Respiratory Medicine, paediatric interstitial lung disease, Humans, Health Care Costs, Longitudinal Studies, Prospective Studies, Patient Acceptance of Health Care, Child, Lung Diseases, Interstitial, paediatric lung disaese
Abstract

BackgroundNo data on healthcare utilisation and associated costs for the many rare entities of children’s interstitial lung diseases (chILD) exist. This paper portrays healthcare utilisation structures among individuals with chILD, provides a pan-European estimate of a 3-month interval per-capita costs and delineates crucial cost drivers.MethodsBased on longitudinal healthcare resource utilisation pattern of 445 children included in the Kids Lung Register diagnosed with chILD across 10 European countries, we delineated direct medical and non-medical costs of care per 3-month interval. Country-specific utilisation patterns were assessed with a children-tailored modification of the validated FIMA questionnaire and valued by German unit costs. Costs of care and their drivers were subsequently identified via gamma-distributed generalised linear regression models.ResultsDuring the 3 months prior to inclusion into the registry (baseline), the rate of hospital admissions and inpatient days was high. Unadjusted direct medical per capita costs (€19 818) exceeded indirect (€1 907) and direct non-medical costs (€1 125) by far. Country-specific total costs ranged from €8 713 in Italy to €28 788 in Poland. Highest expenses were caused by the disease categories ‘diffuse parenchymal lung disease (DPLD)-diffuse developmental disorders’ (€45 536) and ‘DPLD-unclear in the non-neonate’ (€47 011). During a follow-up time of up to 5 years, direct medical costs dropped, whereas indirect costs and non-medical costs remained stable.ConclusionsThis is the first prospective, longitudinal study analysing healthcare resource utilisation and costs for chILD across different European countries. Our results indicate that chILD is associated with high utilisation of healthcare services, placing a substantial economic burden on health systems.

Published
2022

7. Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry

Author

Kreuter, Michael, primary, Kabitz, Hans-Joachim, additional, Hagmeyer, Lars, additional, Hammerl, Peter, additional, Esselmann, Albert, additional, Wiederhold, Conrad, additional, Skowasch, Dirk, additional, Stolpe, Christoph, additional, Joest, Marcus, additional, Veitshans, Stefan, additional, Höffgen, Marc, additional, Maqhuzu, Phillen, additional, Schwarzkopf, Larisa, additional, Hellmann, Andreas, additional, Pfeifer, Michael, additional, Behr, Jürgen, additional, Karpavicius, Rainer, additional, Günther, Andreas, additional, Herth, Felix J. F., additional, and Markart, Philipp, additional

Published
2021
Full Text
View/download PDF

8. Additional file 1 of Cost drivers in the pharmacological treatment of interstitial lung disease

Author

Maqhuzu, Phillen Nozibuyiso, Kreuter, Michael, Bahmer, Thomas, Kahn, Nicolas, Claussen, Martin, Holle, Rolf, and Schwarzkopf, Larissa

Subjects
body regions, respiratory system, behavioral disciplines and activities, respiratory tract diseases
Abstract

Additional file 1: Table S1. List of ‘Other’ ILD subtypes. Table S2. Influencing factors on medical costs at baseline across ILD subtypes in complete cases. Table S3. Influencing factors on longitudinal medication costs across ILD subtypes in complete cases. Table S4. Characteristics of the complete and incomplete cases. Table S5. Frequency of comorbid conditions present at baseline by ILD subtype.

Published
2021
Full Text
View/download PDF

9. Healthcare resource utilisation and medical costs for children with interstitial lung diseases (chILD) in Europe.

Author

Seidl, Elias, Schwerk, Nicolaus, Carlens, Julia, Wetzke, Martin, Cunningham, Steve, Emiralioğlu, Nagehan, Kiper, Nural, Lange, Joanna, Krenke, Katarzyna, Ullmann, Nicola, Krikovszky, Dora, Maqhuzu, Phillen, Griese, Charlotte A., Schwarzkopf, Larissa, Griese, Matthias, and chILD-EU collaborators

Subjects
RESEARCH, RESEARCH methodology, MEDICAL care costs, INTERSTITIAL lung diseases, EVALUATION research, PATIENTS' attitudes, COMPARATIVE studies, LONGITUDINAL method
Abstract

Background: No data on healthcare utilisation and associated costs for the many rare entities of children's interstitial lung diseases (chILD) exist. This paper portrays healthcare utilisation structures among individuals with chILD, provides a pan-European estimate of a 3-month interval per-capita costs and delineates crucial cost drivers.Methods: Based on longitudinal healthcare resource utilisation pattern of 445 children included in the Kids Lung Register diagnosed with chILD across 10 European countries, we delineated direct medical and non-medical costs of care per 3-month interval. Country-specific utilisation patterns were assessed with a children-tailored modification of the validated FIMA questionnaire and valued by German unit costs. Costs of care and their drivers were subsequently identified via gamma-distributed generalised linear regression models.Results: During the 3 months prior to inclusion into the registry (baseline), the rate of hospital admissions and inpatient days was high. Unadjusted direct medical per capita costs (€19 818) exceeded indirect (€1 907) and direct non-medical costs (€1 125) by far. Country-specific total costs ranged from €8 713 in Italy to €28 788 in Poland. Highest expenses were caused by the disease categories 'diffuse parenchymal lung disease (DPLD)-diffuse developmental disorders' (€45 536) and 'DPLD-unclear in the non-neonate' (€47 011). During a follow-up time of up to 5 years, direct medical costs dropped, whereas indirect costs and non-medical costs remained stable.Conclusions: This is the first prospective, longitudinal study analysing healthcare resource utilisation and costs for chILD across different European countries. Our results indicate that chILD is associated with high utilisation of healthcare services, placing a substantial economic burden on health systems. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. Additional file 3 of Determinants of health-related quality of life decline in interstitial lung disease

Author

Maqhuzu, Phillen Nozibuyiso, Boglarka L. Szentes, Kreuter, Michael, Bahmer, Thomas, Kahn, Nicolas, Claussen, Martin, Holle, Rolf, and Schwarzkopf, Larissa

Subjects
respiratory system
Abstract

Additional file 3: Table S3. Differences between ILD subtypes regarding disease duration, number of comorbidities and use of immunosuppressant medication.

Published
2020
Full Text
View/download PDF

18. Treatment and survival diversities in different forms of ILD in Germany - EXCITING registry

Author

Kreuter, Michael, primary, Kabitz, Hans-Joachim, additional, Hagmeyer, Lars, additional, Hammerl, Peter, additional, Esselmann, Albert, additional, Wiederhold, Conrad, additional, Skowasch, Dirk, additional, Stolpe, Christoph, additional, Joest, Marcus, additional, Veitshans, Stefan, additional, Maqhuzu, Phillen, additional, Schwarzkopf, Larissa, additional, Hellmann, Andreas, additional, Pfeifer, Michael, additional, Behr, Jürgen, additional, Kauschka, Dagmar, additional, Günther, Andreas, additional, Herth, Felix J. F., additional, and Markart, Philipp, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results